Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?
Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Sponsor
Sponsor
For Practicing Oncologists
Cancer Science: T-cell/tumor-cell tethering antibody shows promise against refractory non-Hodgkin's lymphoma
Sara Hartley, MDLinx Oncology
Today's Oncology News: The HERS+ to HER2- Switch--Clinically Significant?
D Scott Cunningham MD, PhD, MDLinx Oncology
Noninvasive Biochemical Probe Uses Light to Detect Skin Cancers
Dorothy J. Schirf, MD, MDLinx Oncology
  See all
Niche - Astrocytoma - Immunohistochemistry - Glioblastoma - Survival - Immunofluorescence - Nestin - Tissue array Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
CD133 identifies perivascular niches in grade II–IV astrocytomas
Journal of Neuro-Oncology, 07/17/08
Print     Email This Article     Save in My Library   Free Abstract
Christensen K et al. - A CD133+ perivascular stem cell-like entity exists in astrocytomas. CD133+ tumour vessels may play an important role in a brain tumour stem cell context, while CD133 alone does not appear to be a specific tumour stem cell marker related to patient survival.
 

Sponsor
--- NEUROLOGIC ONCOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email
Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
 Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
 Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
     Medical Students
Nurse Practitioner
Pharma/Drug Marketer
     Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.